Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States.
Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.
The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 15, 22 | -0.08 Increased by +66.67% | -0.07 Decreased by -14.29% |
| May 16, 22 | -0.13 Increased by +38.10% | -0.14 Increased by +7.14% |
| Mar 31, 22 | -0.11 Increased by +54.17% | -0.16 Increased by +31.25% |
| Nov 10, 21 | -0.17 Increased by +22.73% | -0.18 Increased by +5.56% |
| Aug 10, 21 | -0.24 Increased by +7.69% | -0.21 Decreased by -14.29% |
| May 11, 21 | -0.21 Increased by +32.26% | -0.23 Increased by +8.70% |
| Mar 9, 21 | -0.24 Increased by +48.94% | -0.19 Decreased by -26.32% |
| Nov 9, 20 | -0.22 Increased by +61.40% | -0.21 Decreased by -4.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 22 | 0.00 Decreased by N/A% | -8.44 M Increased by +39.63% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -11.81 M Decreased by -1.52% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | 5.46 M Increased by +153.18% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -12.69 M Decreased by -58.14% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -13.97 M Decreased by -100.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 21 | 0.00 Decreased by N/A% | -11.64 M Decreased by -53.41% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 20 | 0.00 Decreased by N/A% | -10.26 M Increased by +9.69% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 20 | 0.00 Decreased by N/A% | -8.03 M Increased by +39.60% | Decreased by N/A% Decreased by N/A% |